Patents Assigned to The Trustees of the University of Pennsylvania
  • Publication number: 20180344886
    Abstract: A device for rapidly sanitizing a surface is described. The device has an enclosure having an opening adapted to insert a surface, and an interior; a liquid nitric oxide solution applicator; and an absorbent material. The liquid nitric oxide solution applicator is in fluid communication with the interior of the enclosure and is adapted to apply liquid nitric oxide solution onto the surface when the surface is positioned within the enclosure. A method of rapidly sanitizing a surface is described. The devices and methods provided herein may be implemented to sanitize the surface of any body part or item that may be placed within the device. An infectious agent on the surface may be killed; i.e., the surface is disinfected. Non-limiting applications of the devices and methods include preventing nosocomial infections or food contamination, sanitizing household items, and implementing sanitizing procedures to comply with FDA Good Manufacturing Practices.
    Type: Application
    Filed: December 29, 2017
    Publication date: December 6, 2018
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Paul H. Axelsen
  • Publication number: 20180344871
    Abstract: The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.
    Type: Application
    Filed: May 12, 2016
    Publication date: December 6, 2018
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andrew TSOURKAS, James z. Hui
  • Patent number: 10138295
    Abstract: A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and a light chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF encode for a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5? and 3? ITRs flank the expression cassettes and regulatory sequences.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 27, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James M. Wilson, Anna Tretiakova
  • Patent number: 10136984
    Abstract: Techniques for mesh augmentation and prevention of incisional hernia, including systems and methods for affixing mesh to a fascial incision. A mesh strip can be integrated with one or more uni-directional fasteners. Each fastener can include an anchoring mechanism adapted for affixation to anterior abdominal wall fascia and a mating interface. An applicator can include tension arms adapted to interface with the mating interfaces of the fasteners to maintain a vertical tension of the mesh strip and a handle coupled with the tension arms adapted to spread the tension arms and thereby control a horizontal tension of the mesh strip. The mesh strip can be configured to be aligned over a fascial incision using the applicator and affixed under tension to anterior abdominal wall fascia by tissue penetration of the anchoring mechanisms of the one or more fasteners.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 27, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: John Patrick Fischer
  • Patent number: 10137176
    Abstract: A vector having an expression cassette having a hIDUA gene having a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurle-Scheie and Scheie syndromes.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: The Trustee of the University of Pennsylvania
    Inventors: James M. Wilson, Brittney L. Gurda
  • Patent number: 10130650
    Abstract: Compositions and methods are provided for the treatment and/or prevention of an inflammatory and/or autoimmune disease or disorder.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: November 20, 2018
    Assignees: The Children's Hospital of Philadelphia, The Trustees of The University of Pennsylvania
    Inventors: Yanping Huang, Janis K. Burkhardt, Taku Kambayashi
  • Patent number: 10130705
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 20, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
  • Patent number: 10122001
    Abstract: The present invention is directed to lithium ion transport media for use in separators in lithium ion batteries, and the membranes, separators, and devices derived therefrom.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 6, 2018
    Assignees: Drexel University, The Trustees of the University of Pennsylvania
    Inventors: Yossef A. Elabd, Karen I. Winey, Yuesheng Ye, Jae-Hong Choi, Tsen-Shan Sharon Sharick
  • Patent number: 10117896
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: November 6, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, Jr., Carl H. June
  • Patent number: 10118936
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 6, 2018
    Assignees: The Trustees of the University of Pennsylvania, AstraZeneca AB
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • Publication number: 20180312810
    Abstract: The presently disclosed subject matter provides systems and methods for producing a three-dimensional model of a human cervix. A microdevice is provided for culturing human cervical cells. The microdevice can include an upper microchannel including live ectocervical epithelial cells. The microdevice can include a lower microchannel including a first parallel lane and a second parallel lane including stromal media. The first and the second parallel lanes can be lined with live vascular endothelial cells. The lower microchannel can include a third parallel lane including uterine fibroblasts and live smooth muscle cells embedded in hydrogel. The first, second, and third lanes of the lower microchannel can be separated by protrusion structures. The third parallel lane can be positioned in the lower microchannel in between the first and the second parallel lanes. The microdevice can further include a porous membrane positioned in between the upper microchannel and the lower microchannel.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 1, 2018
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Dongeun HUH, Jeongyun SEO
  • Publication number: 20180312701
    Abstract: Coatings and methods of using and producing the same are provided. In an exemplary embodiment, a coating includes a first ligand and a second ligand different than the first ligand. The first ligand includes a first carboxylic moiety, a first aromatic moiety, and a first linking moiety connecting the first carboxylic moiety to the first aromatic moiety. the first linking moiety includes an alkene. The second ligand includes a second carboxylic moiety. The coating includes a metal that is a lanthanoid metal, and the coating includes a coating resin.
    Type: Application
    Filed: April 23, 2018
    Publication date: November 1, 2018
    Applicants: AXALTA COATING SYSTEMS IP CO., LLC, The Trustees of the University of Pennsylvania
    Inventors: Eric J. Schelter, Alexander V. Zabula, Robert C. Nahas, Jerome R. Robinson, Eric C. Houze, Gaurang Bhargava, Michael Kerins, JR.
  • Publication number: 20180312595
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: October 6, 2017
    Publication date: November 1, 2018
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Patent number: 10111934
    Abstract: The present disclosure provides for techniques using pro-IGF-I for increasing IGF-I activity. Accordingly, the present disclosure provides for compositions and methods for treating or preventing a disease or disorder mediated by IGF-I. In addition, the present disclosure provides for kits for use in the treatment or prevention of a disease or disorder mediated by IGF-I.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 30, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Elisabeth R. Barton
  • Patent number: 10113182
    Abstract: Recombinant vectors comprise simian adenovirus A1302 (SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 30, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Soumitra Roy, James M. Wilson
  • Patent number: 10113201
    Abstract: An isoform-level gene panel is disclosed that can accurately classify a glioblastoma subtype from a tumor sample. Such an isoform level gene panel comprises the 121 to 214 target isoforms identified in Table 1. Also disclosed are reagents for quantitatively detecting the expression or activity of the target isoforms of Table 1 in a patient sample. For example, such ligands can be PCR primer and probes sets. This isoform-level gene panel and reagents for detection of the isoforms are useful in an isoform-level assay for diagnosis of the molecular subtype of a glioblastoma in a patient. The assay employs algorithms and a novel computer program that performs the functions of FIG. 8. In one aspect, the assay is a high-throughput format.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 30, 2018
    Assignees: The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
    Inventors: Ramana V. Davuluri, Sharmistha Pal, Yingtao Bi, Louise C. Showe, Donald M. O'Rourke, Luke Macyszyn
  • Patent number: 10112895
    Abstract: This invention provides compounds of formulas (I)-(XIV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a molluscum contagiosum virus infection in a subject using compounds or compositions of the invention:
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: October 30, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert P. Ricciardi, Allen B. Reitz, Michael H. Parker, Simon David Peter Baugh, Manunya Nuth, Hancheng Guan
  • Patent number: 10106585
    Abstract: Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine and canine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of a coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous coagulation factor protein.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: October 23, 2018
    Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Inc.
    Inventors: Roland W. Herzog, Henry Daniell
  • Patent number: 10106852
    Abstract: This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated ACVR1 in the diagnosis and treatment of Fibrodysplasia Ossificans Progressiva (FOP).
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: October 23, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Frederick S. Kaplan, Eileen M. Shore
  • Publication number: 20180297039
    Abstract: A magnetic separation filter has an unsupported magnetically soft material layer having a plurality of pores, and, optionally, a passivation layer disposed on the magnetically soft material layer. The magnetic separation filter may be part of a microfluidic device having a lateral flow channel and a vertical flow magnetic separation filter. The magnetic separation device may be used to separate magnetically tagged particles, such as cells.
    Type: Application
    Filed: October 4, 2016
    Publication date: October 18, 2018
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: David Issadore, Venkata Yelleswarapu, Jina Ko